GlassScriptPhysician profile
Douglas B Short
NPI 1922148923
$1,972.86
in general payments reported to CMS, 2019-2025
33 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.23 · 2020: $102 · 2021: $378 · 2022: $190 · 2023: $390 · 2024: $473 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,227.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $277.02 | 2021-2025 | Qulipta, Vraylar |
| Novo Nordisk INC | $260.43 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $242.56 | 2019-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $115.66 | 2021-2025 | Verquvo, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.68 | 2020-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $83.35 | 2020-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $67.59 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $66.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $62.84 | 2020-2025 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $62.13 | 2022-2024 | |
| Astellas Pharma US INC | $59.36 | 2024-2025 | Veozah |
| Abbott Laboratories | $46.33 | 2021-2023 | Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.58 | 2023-2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $41.43 | 2024-2025 | Camzyos |
| Abiomed | $38.84 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $38.61 | 2024 | Intellis Adaptivestim |
| Pfizer INC. | $32.88 | 2023 | |
| Eisai INC. | $32.82 | 2021-2024 | |
| Esperion Therapeutics, INC. | $31.11 | 2020-2023 | Nexletol |
| Gilead Sciences, INC. | $29.79 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $28.77 | 2024 | Rexulti |
| Bausch Health US, LLC | $24.03 | 2021 | |
| Halozyme INC | $20.60 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.67 | 2022 | |
| Antares Pharma, INC. | $19.42 | 2022 | |
| Insulet Corporation | $18.91 | 2025 | Omnipod |
| Endo USA, INC. | $18.84 | 2024 | Aveed |
| Biogen, INC. | $17.30 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.99 | 2022 | |
| Daiichi Sankyo INC. | $16.60 | 2019 | |
| Dexcom, INC. | $15.71 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $14.07 | 2023 | Keveyis |
| Amneal Pharmaceuticals LLC | $12.75 | 2023 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Short listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.